[go: up one dir, main page]

KR930016402A - 항-hiv 활성을 갖는 이미다졸 유도체 - Google Patents

항-hiv 활성을 갖는 이미다졸 유도체 Download PDF

Info

Publication number
KR930016402A
KR930016402A KR1019930000496A KR930000496A KR930016402A KR 930016402 A KR930016402 A KR 930016402A KR 1019930000496 A KR1019930000496 A KR 1019930000496A KR 930000496 A KR930000496 A KR 930000496A KR 930016402 A KR930016402 A KR 930016402A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
hydrogen
halogen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019930000496A
Other languages
English (en)
Other versions
KR100259309B1 (ko
Inventor
히로히꼬 스기모또
마사루 오가따
히로시 마쯔모또
겐-이찌 스기따
아끼히꼬 사또
다미오 후지와라
Original Assignee
시오노 요시히꼬
시오노기 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시오노 요시히꼬, 시오노기 세이야꾸 가부시끼가이샤 filed Critical 시오노 요시히꼬
Publication of KR930016402A publication Critical patent/KR930016402A/ko
Application granted granted Critical
Publication of KR100259309B1 publication Critical patent/KR100259309B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/62—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with triarylmethyl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 신규 이미다졸 유도체 및 그의 약학적으로 허용 가능한 염에 관한 것이다:
상기식에서, R1은 수소, 알킬, 할로겐 또는 선택적으로 치환된 아릴이고; R2는 알킬, 선택적으로 치환된 아릴, 선택적으로 치환된 아르알킬 또는 선택적으로 치환된 이종환 그룹이고; R3은 수소, 알킬, 선택적으로 치환된 이종환 그룹이고; R3은 수소, 알킬, 선택적으로 치환된 아릴, 선택적으로 치환된 아르알킬 또는 선택적으로 치환된 하이드록시 알킬이고; R4는 수소, 알킬, 할로겐, 아실, 선택적으로 치환된 하이드록시 알킬, 선택적으로 에스테르화되거나 아미드화된 카복실 그룹, 하이드록시 그룹, 아릴 또는 아릴티오이고; X는 S, SO, SO2, CH2또는 Se이고, n은 1 내지 3의 정수이고, 상기 신규 이미다졸 유도체는 항-HIV 활성이 있으며 HIV 감염증을 치료하는데 유용하다.

Description

항-HIV 활성을 갖는 이미다졸 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 하기 일반식(Ⅰ)의 화합물 또는 그의 약학적으로 허용가능한 염;
    상기식에서, R1은 수소, 알킬 할로겐 또는 선택적으로 치환된 아릴이고; R2는 알킬 선택적으로 치환된 아릴, 선택적으로 치환된 아르알킬 또는 선택적으로 치환된 이종환 그룹이고; R3은 수소, 알킬, 선택적으로 치환된 아릴, 선택적으로 치환된 아르알킬 또는 선택적으로 치환된 하이드록시 알킬이고; R4는 수소, 알킬, 할로겐, 아실, 선택적으로 치환된 하이드록시 알킬, 선택적으로 에스테르화되거나 아미드화된 카복실 그룹, 하이드록시 그룹, 아릴 또는 아릴티오이고; X는 S, SO, SO2, CH2또는 Se이고, n은 1 내지 3의 정수이다.
  2. 제1항에 있어서, R1이 수소, 저급 알킬, 할로겐 또는 페닐이고; R2가 저급 알킬, 저급 알킬 또는 할로겐으로 선택적으로 치환된 페닐, 또는 필리딜이고; R3이 저급 알킬, 벤질 또는 하이드록시알킬이고; R4가 수소, 저급 알킬, 할로겐, 포르밀, 선택적으로 치환된 하이드록시메틸, 선택적으로 에스테르화되거나 아미드화된 카복실 그룹, 하이드록시 그룹 또는 페닐티오 그룹이고; X가 S 또는 CH2이고, n이 1의 정수인 화합물.
  3. 효과량의 제1항의 화합물을 약학적으로 허용 가능하고 실질적으로 무독성인 담체 또는 부형제와 함께 포함하는 약학적으로 조성물.
  4. 효과량의 제1항의 화합물을 약학적으로 허용 가능한 담체와 함께 포함하는 항바이러스제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930000496A 1992-01-16 1993-01-15 항-hiv 활성을 갖는 이미다졸 유도체 Expired - Fee Related KR100259309B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP92-5577 1992-01-16
JP557792 1992-01-16

Publications (2)

Publication Number Publication Date
KR930016402A true KR930016402A (ko) 1993-08-26
KR100259309B1 KR100259309B1 (ko) 2000-08-01

Family

ID=11615084

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930000496A Expired - Fee Related KR100259309B1 (ko) 1992-01-16 1993-01-15 항-hiv 활성을 갖는 이미다졸 유도체

Country Status (16)

Country Link
US (2) US5326780A (ko)
EP (2) EP0700911B1 (ko)
JP (1) JP3464498B2 (ko)
KR (1) KR100259309B1 (ko)
AT (2) ATE173470T1 (ko)
AU (1) AU649906B2 (ko)
CA (1) CA2087112A1 (ko)
DE (2) DE69330072T2 (ko)
DK (2) DK0552060T3 (ko)
ES (2) ES2125301T3 (ko)
GR (1) GR3035646T3 (ko)
HU (1) HU219917B (ko)
NZ (1) NZ245674A (ko)
PT (1) PT700911E (ko)
TW (1) TW235963B (ko)
ZA (1) ZA93217B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300519A (en) * 1988-07-06 1994-04-05 The University Of Sheffield Immunosuppressive agents
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
MX9702030A (es) * 1994-09-26 1997-06-28 Shionogi & Co Derivado de imidazol.
AU1940897A (en) * 1996-03-28 1997-10-17 Shionogi & Co., Ltd. Lymph-absorbable imidazole derivatives
US5891889A (en) * 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891339A1 (en) * 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0906756A4 (en) * 1996-04-04 2000-11-22 Shionogi & Co ANTI-HIV COMPOSITION CONTAINING IMIDAZOLE DERIVATIVE
US6544193B2 (en) * 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
CN1100763C (zh) * 1996-12-26 2003-02-05 盐野义制药株式会社 咪唑衍生物的制备方法
TWI232214B (en) * 1998-04-16 2005-05-11 Shionogi & Co Preparation of aryl sulfenyl halide
US6184241B1 (en) 1998-08-24 2001-02-06 Kansas State University Research Foundation Aspartic protease inhibitors
BR9917112A (pt) 1998-12-24 2002-01-29 Fujisawa Pharmaceutical Co Compostos de imidazol e seu uso medicinal
GB0028484D0 (en) * 2000-11-22 2001-01-10 Hoffmann La Roche Imidazolone derivatives for the treatment of viral diseases
CN1555365A (zh) * 2001-02-23 2004-12-15 ³�������̴�ѧ�о������� 抑制hiv的n-氨基咪唑衍生物
US10517593B2 (en) 2013-11-04 2019-12-31 Covidien Lp Surgical fastener applying apparatus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63150266A (ja) * 1986-12-12 1988-06-22 Mitsui Petrochem Ind Ltd ベンジルイミダゾ−ル誘導体
US5668136A (en) * 1990-09-25 1997-09-16 Eisai Co., Ltd. Trisubstituted benzene derivatives, composition and methods of treatment

Also Published As

Publication number Publication date
JPH05255270A (ja) 1993-10-05
EP0700911A1 (en) 1996-03-13
DE69330072D1 (de) 2001-05-03
DE69322106D1 (de) 1998-12-24
PT700911E (pt) 2001-07-31
HU219917B (hu) 2001-09-28
ES2125301T3 (es) 1999-03-01
ZA93217B (en) 1993-08-18
ES2157291T3 (es) 2001-08-16
KR100259309B1 (ko) 2000-08-01
TW235963B (ko) 1994-12-11
DE69322106T2 (de) 1999-04-29
US5326780A (en) 1994-07-05
US5472965A (en) 1995-12-05
ATE200082T1 (de) 2001-04-15
JP3464498B2 (ja) 2003-11-10
AU649906B2 (en) 1994-06-02
EP0552060B1 (en) 1998-11-18
NZ245674A (en) 1995-06-27
HU9300107D0 (en) 1993-04-28
ATE173470T1 (de) 1998-12-15
DK0552060T3 (da) 1999-08-02
EP0700911B1 (en) 2001-03-28
DE69330072T2 (de) 2001-08-23
CA2087112A1 (en) 1993-07-17
AU3182793A (en) 1993-07-22
HUT63615A (en) 1993-09-28
EP0552060A1 (en) 1993-07-21
DK0700911T3 (da) 2001-05-07
GR3035646T3 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
KR930016402A (ko) 항-hiv 활성을 갖는 이미다졸 유도체
ES2137915T3 (es) Derivados de tiazolidindiona sustituida.
ATE102193T1 (de) Thiazolidinedionederivate.
KR920007995A (ko) 벤즈아미드 유도체
FI904728A0 (fi) Benzanilider.
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
KR910000638A (ko) 피롤카르복시산 유도체
DE69123757D1 (de) Epoxysuccinamidsäurederivat
KR890011835A (ko) 시스테인 유도체
DE68918298D1 (de) Antibiotikum-Derivat.
KR890008151A (ko) 키놀린 카르복산의 유도체
KR920002613A (ko) 이환성 함유 황화합물
KR920002594A (ko) 5-이소티아졸아민 유도체
KR890005087A (ko) 4- 피페리딘 카르복사미드 유도체
SE8200679L (sv) 1-bensyl-4-(4-(2-pyrimidinylamino) bensyl 1-2,3-dioxopiperazinderivat, salter derav, forfarande for framstellning derav och karcinostatiska medel der de ingar
ES497823A0 (es) Un procedimiento para la preparacion de derivados de tirosi-na.
SE8900256L (sv) Ergolinderivat, deras framstaellning och deras anvaendning
BR9706491A (pt) Compostos de elipticina processo para a sua preparação e composições farmacêuticas contendo os mesmos
KR910000774A (ko) 앙골라마이신 유도체, 그의 제조방법 및 용도
KR940014390A (ko) 3'-o-프로파르길-트리플루오로티미딘의 티오에스테르 유도체, 이의 제조방법 및 이를 유효 성분으로 하는 제암제

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20050309

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060322

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060322